These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16753454)

  • 21. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
    J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoprevention of prostate cancer with finasteride.
    Thompson I; Feigl P; Coltman C
    Important Adv Oncol; 1995; ():57-76. PubMed ID: 7672814
    [No Abstract]   [Full Text] [Related]  

  • 24. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
    Serfling R; Shulman M; Thompson GL; Xiao Z; Benaim E; Roehrborn CG; Rittmaster R
    J Urol; 2007 Jun; 177(6):2352-6. PubMed ID: 17509357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.
    Orvieto M; Eggener S
    Eur Urol; 2009 May; 55(5):1073-4. PubMed ID: 19200640
    [No Abstract]   [Full Text] [Related]  

  • 26. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
    Mellon JK
    Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
    Villers A
    Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New finasteride trial results aim to curb controversy.
    Bankhead C
    J Natl Cancer Inst; 2006 Aug; 98(16):1104-5. PubMed ID: 16912260
    [No Abstract]   [Full Text] [Related]  

  • 29. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of finasteride in prostate cancer].
    Altarac S
    Lijec Vjesn; 2004; 126(1-2):48. PubMed ID: 15526752
    [No Abstract]   [Full Text] [Related]  

  • 32. [Is tumour grade applicable to finasteride-treated prostate cancer?].
    Molinié V; Ruffion A; Allory Y; Leroy X; Cochand Priollet B; Paraf F; de la Taille A
    Prog Urol; 2005 Jun; 15(3):387-91. PubMed ID: 16097140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guideline for 5-alpha-reductase inhibitors in the prevention of prostate cancer is premature.
    Frankel PH; Twardowski P
    J Clin Oncol; 2009 Oct; 27(30):e164; author reply e165. PubMed ID: 19738114
    [No Abstract]   [Full Text] [Related]  

  • 35. A woman with iatrogenic androgenetic alopecia responding to finasteride.
    Hong JB; Chiu HC; Chan JY; Chen RJ; Lin SJ
    Br J Dermatol; 2007 Apr; 156(4):754-5. PubMed ID: 17263815
    [No Abstract]   [Full Text] [Related]  

  • 36. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
    Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
    Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolution of the PCPT from clinical to molecular analyses.
    Hoque A
    Nat Clin Pract Oncol; 2006 Nov; 3(11):581. PubMed ID: 17080169
    [No Abstract]   [Full Text] [Related]  

  • 38. Finasteride and high-grade prostate cancer.
    Edwards JL
    Cancer Prev Res (Phila); 2009 Feb; 2(2):185; author reply 185. PubMed ID: 19174583
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostate cancer prevention (AUGUST 2009).
    Keller DL
    Cleve Clin J Med; 2009 Nov; 76(11):630; author reply 630. PubMed ID: 19884290
    [No Abstract]   [Full Text] [Related]  

  • 40. Study of prostate cancer prevention drug shows potential and problems.
    Levenson D
    Rep Med Guidel Outcomes Res; 2003 Jul; 14(13):8-10. PubMed ID: 12918518
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.